Methylated of genes behaving as potential biomarkers in evaluating malignant degree of glioblastoma.
Abnormal methylation genes usually act as oncogenes or anti-oncogenes in the occurrence and development of tumor, indicating their potential role as biomarkers in the evaluation of malignant tumor. However, the research on methylation's association with glioblastoma was rare. We attempted to figure out whether the methylation of genes could serve as the biomarker in evaluating the malignant degree of GBM. Methylation microarray data of 275 GBM patients have been downloaded from The Cancer Genome Atlas (TCGA) dataset. Logistic regression was used to find the methylated genes associated with the malignant degree of patients with the tumor. Functional enrichment analysis and network analysis were further performed on these selected genes. A total of 668, 412, 470, and 620 genes relevant with the methylation or demethylation were found to be associated with the malignant degree, Grades 1-4 of tumor. The higher the degree of malignant tumor, the higher of its methylation degree of its corresponding genes. GO and KEGG analysis results showed that these methylated genes were enriched in many functions as cell adhesion, abnormal transcription, and cell cycle disorder, etc. Of note, CCL11 and LCN11 were found to be significantly related to the progression of GBM. Critical genes associated with cell cycle as CCL11 and LCN1 may play essential roles in the occurrence, development, and transition of glioblastoma. More research was needed to explore its potential molecular mechanism.
Department of Rehabilitation Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang Province, China.
Wan-Shun
WS
Wen
Department of Neurosurgery, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China.
Sheng-Li
SL
Hu
Department of Neurology, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei Province, China.
Zhibing
Z
Ai
Department of Ophthalmology, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Longmatan District, Luzhou, China.
Lin
L
Mou
Department of Neurology, The Second People's Hospital of Huai'an, The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China.
Jing-Min
http://orcid.org/0000-0001-8311-1002
JM
Lu
Department of Spinal Surgery, Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Longmatan District, Luzhou, China.
Sen
S
Li
D014408:Biomarkers, Tumor / Q000235:genetics*; D001932:Brain Neoplasms / Q000235:genetics* / Q000473:pathology; D054413:Chemokine CCL11 / Q000235:genetics; D016009:Chi-Square Distribution; D019295:Computational Biology; D019175:DNA Methylation; D030541:Databases, Genetic; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D053263:Gene Regulatory Networks; D005909:Glioblastoma / Q000235:genetics* / Q000473:pathology; D006801:Humans; D054834:Lipocalins / Q000235:genetics; D016015:Logistic Models; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D020411:Oligonucleotide Array Sequence Analysis
D014408:Biomarkers, Tumor; C515456:CCL11 protein, human; D054413:Chemokine CCL11; D054834:Lipocalins
biomarkers; glioblastoma; mRNA; malignant degree; methylation